Cargando…

P233 COVID-19-a ssociated Mucormycosis: an experience of invasive fungal sinusitis from a tertiary care referral center in Northern India

POSTER SESSION 2, SEPTEMBER 22, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: The study was aimed to determine the patient demographics, risk factors, which include comorbidities, presenting symptoms and signs, medications used to treat COVID-19, species of Mucorales isolated, and the management outcome o...

Descripción completa

Detalles Bibliográficos
Autores principales: Marak, Rungmei S K, Chaudhary, Radhika, Keshri, Amit Kumar, Baghel, Surendra Singh, Manogaran, Ravi Sankar, Dixit, Ajai Kumar, Mishra, Prabhakar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494504/
http://dx.doi.org/10.1093/mmy/myac072.P233
_version_ 1784793808964157440
author Marak, Rungmei S K
Chaudhary, Radhika
Keshri, Amit Kumar
Baghel, Surendra Singh
Manogaran, Ravi Sankar
Dixit, Ajai Kumar
Mishra, Prabhakar
author_facet Marak, Rungmei S K
Chaudhary, Radhika
Keshri, Amit Kumar
Baghel, Surendra Singh
Manogaran, Ravi Sankar
Dixit, Ajai Kumar
Mishra, Prabhakar
author_sort Marak, Rungmei S K
collection PubMed
description POSTER SESSION 2, SEPTEMBER 22, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: The study was aimed to determine the patient demographics, risk factors, which include comorbidities, presenting symptoms and signs, medications used to treat COVID-19, species of Mucorales isolated, and the management outcome of COVID-19-associated mucormycosis. METHODS: It was a 6-month retrospective, propensity score-matched, comparative study conducted at a tertiary care center, involving 124 patients with COVID-19 associated mucormycosis admitted between April and September 2021, who were suffering from or had a history of COVID-19 infection. RESULTS: Among the 124 patients, 87 were male, and 37 were female. A total of 72.6% of patients received steroids, while 73.4% received antibiotics, and 55.6% received oxygen during COVID-19 management. The most common comorbidities were diabetes mellitus (83.9%) and hypertension (30.6%). A total of 92.2% had mucor, 16.9% had Aspergillus, 12.9% had both, and one patient had hyalohyphomycosis on fungal smear and culture. The comparative study showed the significant role of serum ferritin, glycemic control, steroid use, and duration in COVID-19-associated invasive fungal disease (P <.001). Headache and facial pain (68, 54.8%) were the most common symptoms. The most involved sinonasal site was the maxillary sinus (90, 72.6%). Direct KOH microscopy for fungus was positive in 100% of the cases, 82.2% were Mucorales; 12.9% showed mixed fungal hyphae (mucormycetes and Aspergillus spp.), 4% Aspergillus and hyaline septate non-Aspergillus fungus hyphae were seen in 0.8%. Mucoraceous fungi isolated were R. arrhizus, R. microsporus, R. homothallicus, Rhizomucor pusillus, and Leithemia corymbifera. The overall survival rate at the 3-month follow-up was 79.9%. CONCLUSION: COVID-19-related aggressive inflammatory response, uncontrolled glycemic level, and rampant use of steroids are the most important predisposing factors in developing COVID-19-associated invasive fungal sinusitis caused by Mucorales. A high index of suspicion, aggressive surgical and antifungal therapy resulted in the successful outcomes for most of the patients.
format Online
Article
Text
id pubmed-9494504
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-94945042022-09-26 P233 COVID-19-a ssociated Mucormycosis: an experience of invasive fungal sinusitis from a tertiary care referral center in Northern India Marak, Rungmei S K Chaudhary, Radhika Keshri, Amit Kumar Baghel, Surendra Singh Manogaran, Ravi Sankar Dixit, Ajai Kumar Mishra, Prabhakar Med Mycol Oral Presentations POSTER SESSION 2, SEPTEMBER 22, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: The study was aimed to determine the patient demographics, risk factors, which include comorbidities, presenting symptoms and signs, medications used to treat COVID-19, species of Mucorales isolated, and the management outcome of COVID-19-associated mucormycosis. METHODS: It was a 6-month retrospective, propensity score-matched, comparative study conducted at a tertiary care center, involving 124 patients with COVID-19 associated mucormycosis admitted between April and September 2021, who were suffering from or had a history of COVID-19 infection. RESULTS: Among the 124 patients, 87 were male, and 37 were female. A total of 72.6% of patients received steroids, while 73.4% received antibiotics, and 55.6% received oxygen during COVID-19 management. The most common comorbidities were diabetes mellitus (83.9%) and hypertension (30.6%). A total of 92.2% had mucor, 16.9% had Aspergillus, 12.9% had both, and one patient had hyalohyphomycosis on fungal smear and culture. The comparative study showed the significant role of serum ferritin, glycemic control, steroid use, and duration in COVID-19-associated invasive fungal disease (P <.001). Headache and facial pain (68, 54.8%) were the most common symptoms. The most involved sinonasal site was the maxillary sinus (90, 72.6%). Direct KOH microscopy for fungus was positive in 100% of the cases, 82.2% were Mucorales; 12.9% showed mixed fungal hyphae (mucormycetes and Aspergillus spp.), 4% Aspergillus and hyaline septate non-Aspergillus fungus hyphae were seen in 0.8%. Mucoraceous fungi isolated were R. arrhizus, R. microsporus, R. homothallicus, Rhizomucor pusillus, and Leithemia corymbifera. The overall survival rate at the 3-month follow-up was 79.9%. CONCLUSION: COVID-19-related aggressive inflammatory response, uncontrolled glycemic level, and rampant use of steroids are the most important predisposing factors in developing COVID-19-associated invasive fungal sinusitis caused by Mucorales. A high index of suspicion, aggressive surgical and antifungal therapy resulted in the successful outcomes for most of the patients. Oxford University Press 2022-09-20 /pmc/articles/PMC9494504/ http://dx.doi.org/10.1093/mmy/myac072.P233 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oral Presentations
Marak, Rungmei S K
Chaudhary, Radhika
Keshri, Amit Kumar
Baghel, Surendra Singh
Manogaran, Ravi Sankar
Dixit, Ajai Kumar
Mishra, Prabhakar
P233 COVID-19-a ssociated Mucormycosis: an experience of invasive fungal sinusitis from a tertiary care referral center in Northern India
title P233 COVID-19-a ssociated Mucormycosis: an experience of invasive fungal sinusitis from a tertiary care referral center in Northern India
title_full P233 COVID-19-a ssociated Mucormycosis: an experience of invasive fungal sinusitis from a tertiary care referral center in Northern India
title_fullStr P233 COVID-19-a ssociated Mucormycosis: an experience of invasive fungal sinusitis from a tertiary care referral center in Northern India
title_full_unstemmed P233 COVID-19-a ssociated Mucormycosis: an experience of invasive fungal sinusitis from a tertiary care referral center in Northern India
title_short P233 COVID-19-a ssociated Mucormycosis: an experience of invasive fungal sinusitis from a tertiary care referral center in Northern India
title_sort p233 covid-19-a ssociated mucormycosis: an experience of invasive fungal sinusitis from a tertiary care referral center in northern india
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494504/
http://dx.doi.org/10.1093/mmy/myac072.P233
work_keys_str_mv AT marakrungmeisk p233covid19associatedmucormycosisanexperienceofinvasivefungalsinusitisfromatertiarycarereferralcenterinnorthernindia
AT chaudharyradhika p233covid19associatedmucormycosisanexperienceofinvasivefungalsinusitisfromatertiarycarereferralcenterinnorthernindia
AT keshriamitkumar p233covid19associatedmucormycosisanexperienceofinvasivefungalsinusitisfromatertiarycarereferralcenterinnorthernindia
AT baghelsurendrasingh p233covid19associatedmucormycosisanexperienceofinvasivefungalsinusitisfromatertiarycarereferralcenterinnorthernindia
AT manogaranravisankar p233covid19associatedmucormycosisanexperienceofinvasivefungalsinusitisfromatertiarycarereferralcenterinnorthernindia
AT dixitajaikumar p233covid19associatedmucormycosisanexperienceofinvasivefungalsinusitisfromatertiarycarereferralcenterinnorthernindia
AT mishraprabhakar p233covid19associatedmucormycosisanexperienceofinvasivefungalsinusitisfromatertiarycarereferralcenterinnorthernindia